New ALS drug shows promise in slowing disease
NCT ID NCT05740813
Summary
This trial tested whether the drug ABBV-CLS-7262 could slow the progression of ALS (amyotrophic lateral sclerosis) and improve survival. It involved 310 people with ALS who were randomly assigned to receive either the drug or a placebo for 24 weeks. Researchers measured changes in physical function, breathing ability, and survival to see if the drug was effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Healey Center for ALS at Mass General
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.